Free Trial
Discover Investing Tools for the A.I EraGet 30 Days Free

Short Interest in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Rises By 100.0%

Written by MarketBeat
Updated September 19, 2025
OKYO Pharma logo with Medical background

Key Points

  • Short interest in OKYO Pharma Limited's stock surged by 100% in August, increasing to 31,000 shares from 15,500 shares.
  • The company's stock price decreased by $0.02 to $2.15 during Friday's trading, with a 52-week price range between $0.90 and $3.35.
  • Analysts have a consensus rating of "Buy" for OKYO Pharma, with a price target set at $7.00.
  • Five stocks we like better than OKYO Pharma.

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a significant increase in short interest during the month of August. As of August 31st, there was short interest totaling 31,000 shares, an increase of 100.0% from the August 15th total of 15,500 shares. Approximately 0.1% of the company's stock are short sold. Based on an average daily trading volume, of 175,000 shares, the short-interest ratio is presently 0.2 days. Based on an average daily trading volume, of 175,000 shares, the short-interest ratio is presently 0.2 days. Approximately 0.1% of the company's stock are short sold.

OKYO Pharma Stock Performance

Shares of OKYO traded down $0.09 during midday trading on Friday, hitting $1.98. 249,031 shares of the stock traded hands, compared to its average volume of 53,657. OKYO Pharma has a 1-year low of $0.90 and a 1-year high of $3.35. The business's 50 day moving average price is $2.57 and its two-hundred day moving average price is $2.01.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on OKYO shares. Zacks Research upgraded shares of OKYO Pharma to a "hold" rating in a research note on Tuesday. Wall Street Zen upgraded shares of OKYO Pharma to a "hold" rating in a research note on Saturday, August 9th. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, OKYO Pharma has a consensus rating of "Moderate Buy" and a consensus price target of $7.00.

Check Out Our Latest Research Report on OKYO

Institutional Trading of OKYO Pharma

Hedge funds have recently bought and sold shares of the company. FNY Investment Advisers LLC purchased a new stake in shares of OKYO Pharma in the first quarter worth approximately $25,000. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of OKYO Pharma during the second quarter worth $28,000. Finally, Dauntless Investment Group LLC acquired a new stake in OKYO Pharma during the first quarter valued at $2,526,000. 2.97% of the stock is owned by hedge funds and other institutional investors.

About OKYO Pharma

(Get Free Report)

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.

Featured Stories

Should You Invest $1,000 in OKYO Pharma Right Now?

Before you consider OKYO Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OKYO Pharma wasn't on the list.

While OKYO Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover
7 Stocks to Ride The A.I. Megaboom


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.